Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Joins the NASDAQ Biotechnology Index

Business Wire December 26, 2013

Annual Changes to the NASDAQ Biotechnology Index

Globe Newswire December 16, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on ADHD, BLUE, STML and XLRN

Accesswire December 11, 2013

bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia

Business Wire December 2, 2013

bluebird bio to Present at Deutsche Bank BioFEST Conference

Business Wire November 27, 2013

bluebird bio Reports Fiscal Third Quarter 2013 Financial Results

Business Wire November 14, 2013

bluebird bio Announces First Patient Transplanted in Phase 2/3 Starbeam ALD-102 Study for the Treatment of CCALD

Business Wire October 28, 2013

bluebird bio Joins the Russell 2000® Index

Business Wire October 1, 2013

Richard Morgan, Ph.D. Joins bluebird bio as Vice President of Immunotherapy

Business Wire October 1, 2013

Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013

PR Newswire September 6, 2013

bluebird bio to Present at Morgan Stanley Global Healthcare Conference

Business Wire September 4, 2013

bluebird bio Selected As A 2014 Technology Pioneer By The World Economic Forum

Business Wire August 27, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BLUE, CMRX, CNAT and ICEL

Accesswire August 26, 2013

bluebird bio Reports Fiscal Second Quarter 2013 Financial Results

Business Wire August 14, 2013

bluebird bio to Present at Two Upcoming Conferences

Business Wire August 6, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on AXAS, BLUE, ONXX and TROV

Accesswire July 16, 2013

bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

Business Wire June 24, 2013